RxDoctor Payments Data

William Geisler, MD

Infectious Disease · Birmingham, ALNPI 1740224989

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (42.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Sanofi Pasteur Inc. at 55.9% of the total. Reporting peaked in 2023 at $33,899 and has fallen 89.9% since, to $3,413 in 2025. Among infectious disease clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$62,938in general payments, 2019–2025

Across 37 payments — averaging $1701.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi Pasteur Inc.$35K
  • Gen-probe, Inc.$9K
  • Roche Diagnostics Corporation$5K
  • Roche Molecular Systems, Inc.$4K
  • GSK$3K
  • Gen-probe Sales & Service, Inc.$3K
  • plus $4K from 5 others

What the payments were for

  • Consulting fees$26,70242%
  • Speaking & faculty fees$19,07730%
  • Travel & lodging$16,07526%
  • Food & beverage$1,0842%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sanofi Pasteur Inc.9$35,202
Gen-probe, Inc.6$8,813
Roche Diagnostics Corporation4$4,818
Roche Molecular Systems, Inc.3$4,072
GSK3$3,413
Gen-probe Sales & Service, Inc.2$2,792
Merck1$1,395
Abbott2$1,306
Hologic Sales And Service, LLC4$515
Visby Medical, Inc.1$500
BD2$112

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$62,938 in reported general payments places this provider in the 90th percentile of 104 infectious disease providers in Alabama.

See all infectious disease providers in Alabama

Medicare billing

Part B allowed, 2024
$5,572
Medicare patients
21
Services billed
61

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other infectious disease in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →